The latest news on the growing cost of conducting clinical trials is becoming a major concern for company sponsors and trial co-operative groups.
Mukhtar Ahmed
Advertisement
Mukhtar Ahmed is Vice President, Product Strategy, Oracle Health Sciences.
Articles by Mukhtar Ahmed
Mukhtaer Ahmed outlines how advances in machine-to-machine (M2M) technologies have the potential to transform clinical development programs, including clinical trials.
Advertisement
Latest Updated Articles
- The Future is Now: Leveraging Machine-to-Machine Technology to Advance Clinical Trials
Published: October 22nd 2013 | Updated:
- Risk-Based Monitoring: From the Road Less Traveled to Productivity Superhighway
Published: February 24th 2014 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Johnson and Johnson Reveals Plan to Separate Orthopaedics Business
2
The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.
3
The Evolving Landscape in Psychiatry: Challenges and Opportunities for Biopharma
4
Nabla Bio Enters $1 Billion Multi-Year Research Collaboration with Takeda
5
